$TWST

Cho Dennis sold $87K of TWST

Cho Dennis (See Remarks) sold 1,642 shares of Twist Bioscience Corp (TWST) at $53.26 on 2026-05-21.

Original reporting
SEC EDGAR · Cho Dennis
Published May 26, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Because this is only an ownership-change disclosure without accompanying company events, it is more relevant for short-term sentiment than for forecasting earnings or fundamental re-rating.

02

Market read

Traders may monitor insider activity as a sentiment input, but the disclosure alone is unlikely to drive a durable move absent corroborating fundamental news.

03

What to watch

The article lacks context on total insider holdings changes over time, whether other insiders sold/bought, and whether the sale was part of broader compensation/stock management.

Relevance 6/10Timing: Immediate awareness for sentiment/positioning; limited follow-through expected.

Background

The article reports an SEC Form 4 insider transaction by Dennis Cho (officer) at Twist Bioscience, including trade date, share count, and post-transaction holdings.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Dennis Cho sold $87.4K of TWST shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low probability of sustained price impact; any reaction is likely limited to short-term sentiment/positioning.

Evidence & confidence

The filing is a routine insider transaction disclosure (Form 4) without accompanying operational or financial news, and the article provides no new guidance, deal, or regulatory outcome.

Market effects

Minimal; insider sale does not change biotech/biomanufacturing fundamentals or sector expectations based on provided details.

None indicated; disclosure is company-specific.

None indicated; no international transaction, trial, or regulatory event described.

Counterpoint

Insider sales are often planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Twist Bioscience Corp

    Subject of the SEC Form 4 insider sale: 1,642 shares sold at $53.2570 on 2026-05-21; holdings after sale 134,299 shares.

  • Dennis Cho

    Reported seller of TWST shares; open-market sale disclosed on SEC EDGAR.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.